Otterspoor Luuk C, van Nunen Lokien X, van 't Veer Marcel, Johnson Nils P, Pijls Nico H J
1 Department of Cardiology, Catharina Hospital , Eindhoven, the Netherlands .
2 Department of Biomedical Engineering, Eindhoven University of Technology , Eindhoven, the Netherlands .
Ther Hypothermia Temp Manag. 2017 Dec;7(4):199-205. doi: 10.1089/ther.2017.0006. Epub 2017 May 18.
Because current reperfusion strategies in acute myocardial infarction (AMI) seem to be exhausted in terms of additional mortality benefit, there remains a need for new methods to attenuate reperfusion injury and, thereby, further reduce myocardial infarct size and improve long-term survival. Therapeutic hypothermia (32-35°C) diminishes reperfusion injury and reduces infarct size in a variety of animal models of AMI if provided before reperfusion. In human studies this reduction has not been confirmed so far, most likely because systemic cooling acts slowly, and therefore, the target temperature is not reached in time or at all in a substantial number of patients. Furthermore, systemic cooling can cause adverse effects such as severe shivering, volume overload, and an enhanced adrenergic state. In most randomized clinical trials, however, subgroups of patients with anterior myocardial infarction that reached the target temperature before reperfusion did show a reduction in infarct size. To transform therapeutic hypothermia into a clinically feasible treatment for AMI, its method must be modified. An ideal technique should be quick enough to achieve sufficient myocardial hypothermia before reperfusion, without significant delay and without the adverse effects of systemic cooling. In this review, we propose a novel, potentially feasible method of selective intracoronary hypothermia to overcome the problems encountered with prior techniques.
由于急性心肌梗死(AMI)目前的再灌注策略在进一步降低死亡率方面似乎已达到极限,因此仍需要新的方法来减轻再灌注损伤,从而进一步缩小心肌梗死面积并提高长期生存率。治疗性低温(32 - 35°C)如果在再灌注前实施,可减轻多种AMI动物模型的再灌注损伤并缩小梗死面积。在人体研究中,目前尚未证实这种梗死面积的缩小,很可能是因为全身降温起效缓慢,因此,相当数量的患者无法及时或根本无法达到目标温度。此外,全身降温可导致诸如严重寒战、容量超负荷和肾上腺素能状态增强等不良反应。然而,在大多数随机临床试验中,在再灌注前达到目标温度的前壁心肌梗死患者亚组确实显示梗死面积有所缩小。为了将治疗性低温转变为一种临床上可行的AMI治疗方法,必须改进其方法。一种理想的技术应该足够快,能够在再灌注前实现足够的心肌低温,且无明显延迟,也没有全身降温的不良反应。在这篇综述中,我们提出一种新型的、可能可行的选择性冠状动脉内低温方法,以克服现有技术所遇到的问题。